Cite

HARVARD Citation

    Guo, B. et al. (2019). A utility‐based Bayesian phase I–II design for immunotherapy trials with progression‐free survival end point. Journal of the Royal Statistical Society. 68 (2), pp. 411-425. [Online]. 
  
Back to record